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Abstract
Background: More than 50% of patients undergoing lifelong suppressive antiviral treatment for HIV-1 infection
develop minor HIV-1-associated neurocognitive disorders. Neurological complications during HIV-1 infection are the
result of direct neuronal damage by proinflammatory products released from HIV-1-infected or -uninfected
activated lymphocytes, monocytes, macrophages, microglia and astrocytes. The specific pro-inflammatory products
and their roles in neurotoxicity are far from clear. We investigated proinflammatory cytokines and chemokines in
the cerebrospinal fluid (CSF) of HIV-demented (HIV-D) and HIV-nondemented (HIV-ND) patients and studied their
affect on neuroglial toxicity.
Methods and results: Bioplex array showed elevated levels of signatory chemokines or cytokines (IL-6, IFN-γ,
CXCL10, MCP-1 and PDGF) in the CSF of HIV-D patients (n = 7) but not in that of HIV-ND patients (n = 7). Among
the signatory cytokines and chemokines, CXCL10 was distinctly upregulated in-vitro in HIV-1 (NLENG1)-activated
human fetal astrocytes, HIV-1 (Ba-L)-infected macrophages, and HIV-1 (NLENG1)-infected lymphocytes. Virus-infected
macrophages also had increased levels of TNF-α. Consistently, human fetal astrocytes treated with HIV-1 and TNF-α
induced the signatory molecules. CXCL10 in combination with HIV-1 synergistically enhanced neuronal toxicity and
showed chemotactic activity (~ 40 fold) for activated peripheral blood mononuclear cells (PBMC), suggesting the
intersection of signaling events imparted by HIV-1 and CXCL10 after binding to their respective surface receptors,
CXCR4 and CXCR3, on neurons. Blocking CXCR3 and its downstream MAP kinase (MAPK) signaling pathway
suppressed combined CXCL10 and HIV-1-induced neurotoxicity. Bryostatin, a PKC modulator and suppressor of
CXCR4, conferred neuroprotection against combined insult with HIV-1 and CXCL10. Bryostatin also suppressed HIV-1
and CXCL10-induced PBMC chemotaxis. Although, therapeutic targeting of chemokines in brain may have adverse
consequences on the host, current findings and earlier evidence suggest that CXCL10 could strongly impede
neuroinflammation.
Conclusion: We have demonstrated induction of CXCL10 and other chemokines/cytokines during HIV-1 infection
in the brain, as well as synergism of CXCL10 with HIV-1 in neuronal toxicity, which was dampened by bryostatin.
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HIV-1 infection programs aberrant host immune
responses, including those in the brain that contribute
to neuropathogenesis [1]. HIV infection in the brain is
characterized by the formation of multinucleated giant
cells (MNGCs), microglial nodules, and astrocytosis,
which result in neuronal damage and loss of dendrites.
About 25% of untreated patients with chronic HIV-1
infection develop HIV-associated dementia (HAD).
More than 50% of successfully treated patients develop
mild neurological deficits known as HIV-1-associated
neurocognitive disorders. Unfolding the mechanism of
neuronal damage can lead to the identification of new
therapeutic drug targets. M-tropic HIV-1 infects macro-
phages and microglia in the brain, but both M-tropic
and T-tropic HIV-1 populations were also found on
autopsy of central nervous tissues and cerebrospinal fluid
(CSF) of HAD patients [2-5]. HIV-1-derived proteins,
including envelope, Tat, Nef, and Vpr cause direct neuronal
damage. In addition, neurotoxic inflammatory products
have been implicated in neuronal damage [6-10]. These
products include proinflammatory cytokines and chemo-
kines derived from HIV-1 infected- or uninfected- activated
lymphocytes, macrophages, microglia, and astrocytes.
TNF-α is a monocyte-derived proinflammatory cytokine
[11]. Its immunoreactivity has been reported in frontal
white matter from the autopsied brains of patients with
HIV-1 infection [12]. During HIV-1 infection in the brain,
activated macrophage- and microglia-secreted TNF-α acts
in an autocrine and paracrine manner that, in combin-
ation with viral proteins, amplifies immunological and
inflammatory responses in the central nervous system
(CNS) [13-17]. Membrane-bound TNF-α on monocyte-
derived macrophages (MDM) causes astrocyte toxicity by
cell-to-cell contact [18]. Overexpression of TNF-α in vivo
causes T-cell infiltration in the CNS, as well as astrocytosis,
microgliosis, and demyelination [19]. Astrocytes respond
to TNF-α with increases in CXCR3, CCR3, and CXCR1
receptors [20], as well as CXCL10 [21], resulting in trans-
duction of downstream signals via binding of cytokine or
chemokine ligands.
CXCL10, a 10-kDa IFN-γ-induced protein (IP-10)
belonging to the CXC chemokine family, is secreted in re-
sponse to IFN-γ from different cells, including monocytes,
endothelial cells, fibroblasts, astrocytes, and lymphocytes
[22,23]. CXCL10 elicits its effects by binding to chemokine
receptor CXCR3 [24]. Elevated levels of CXCL10 correlate
with the development of HIV-D [25] and are associated
with other CNS disorders [26-31].
HIV proteins such as gp120, Nef, and Tat induce
CXCL10 [32-34]. A few studies have shown a correlation
between elevated levels of CXCL10 in the CSF and
plasma of individuals with HIV-1 infection and the
association of CXCL10 with the severity of clinical
symptoms [9,25,35-37]. In addition, brain tissues from
individuals with HAD have been shown to have elevated
mRNA levels of CXCL10 [32]. Chronic expression of
monocyte chemotactic protein (MCP)-1 and CXCL10 in
HIV-1-infected brains increases the migration of mono-
cytes and CXCR3+ T-cells into the brain [37-40].
Current antiretroviral therapy has significantly reduced
the severity of HIV-1 and neurological complications.
However, residual viral activity, consequent neuroinflam-
mation, and immune activation continue to account for
neurological complications [41]. Lack of anti-inflammatory
and HIV-1 transcriptional repressors in current antiviral
therapy require a search for new anti-inflammatory and
neuroprotective agents. Bryostatin, a macrocyclic lactone
isolated from endosymbiont γ-proteobacterial Endobugula
sertula [42], is an activator of protein kinase C (PKC) and
has been shown to have diverse biological activities.
Recently, we and others have shown that bryostatin has
anti-HIV-1 activity via various mechanisms, such as block-
ing the effect of stromal-cell-derived factor-1 (SDF-1),
which it does by down regulating its CXCR4 receptors
[43] or modulating CD4 and CXCR4 receptors [44,45].
Bryostatin is currently being used in a phase I clinical trial
in patients with nonhematologic tumors, and in a phase II
trial for relapsed multiple myeloma [46,47]. In the brain,
bryostatin specifically activates PKC epsilon, resulting in
neurite extension and the development of long-term
memory and neuroprotection [48-50].
Although several studies have been published on
proinflammatory products in HIV-1-demented patients,
no guidelines are available for selective targeting of
proinflammatory molecules. In the current study, we
investigated the proinflammatory response in the CSF of
HIV-1-infected demented and nondemented patients. We
further investigated whether HIV-1 infection (M-tropic) in
macrophages or treatment of astrocytes with TNF-α and
HIV-1 (T-tropic or M-tropic) provoked the same proin-
flammatory response as that in patients. We have shown
that HIV-1 infection in macrophages or treatment of astro-
cytes with TNF-α and HIV-1 modulates CXCL10 expres-
sion, which leads to neuro-toxicity. We further investigated
whether bryostatin, a PKC activator, confers neuroprotec-
tion against combined HIV-1 and CXCL10 insult.
Materials and methods
Cerebrospinal fluid samples
CSF samples from seven HIV-1-infected demented
(HIV-D) patients and seven HIV-1-infected nondemented
(HIV-ND) patients were obtained through the National
NeuroAIDS Tissue Consortium (NNTC, Rockville, MD,
USA) and were IRB exempt. The ages of HIV-D patients
ranged from 33 to 52 years, with a median age of 41 years;
that of HIV-ND patients ranged from 36 to 50 years, with a
median of 39 years. Six HIV-D patients were African-
Mehla et al. Journal of Neuroinflammation 2012, 9:239 Page 2 of 19
http://www.jneuroinflammation.com/content/9/1/239American males; one was female, with viral load ranging
from 50 to 512. All HIV-ND patients were white and male,
with undetectable viral load except for two patients with 69
and 19 viral copies respectively. Before testing, CSF samples
were thawed, spun briefly to remove the precipitated pro-
teins, and diluted 1:2 with optiMEM. The diluted samples
were tested in a custom made ten-plex array (Bio-Rad).
Primary human brain cultures, peripheral blood
mononuclear cells (PBMCs), and cell lines
Primary human brains at 8 to 12 weeks gestational age
obtained from the University of Washington, Seattle
were cultured as described earlier [51,52]. Briefly, men-
inges and blood vessels were removed from the brain
cortex. The tissue was washed twice with optiMEM con-
taining 1% penicillin-streptomycin and amphotericin-B
(GibcoBRL). The cortex tissues were mechanically
disrupted by passing them once through a 20-ml syringe
without a needle. Disrupted cortex tissue was centrifuged at
1,200 rpm for 20 minutes at 4°C. For differentiation to
astrocytes, cell pellets were resuspended in DMEM
supplemented with antibiotics and 10% FCS negative for
Mycoplasma sps. For differentiation to neurons, pellets
were resuspended in opti-MEM medium and cultured in
Opti-MEM supplemented with 5% FCS, 0.2% N2 supple-
ment (GibcoBRL), and antibiotics. The purity of cultures
was established by immunostaining either microtubule-
associated protein-2 (Sigma) for neurons or glial fibrillary
acidic protein (GFAP) for astrocytes.
Primary human fetal neuron (HFN) and astrocyte
(HFA) cultures were maintained for at least a month be-
fore use. Astrocytes were used at the second or third
passage to discourage growth of contaminating micro-
glia. Cultures derived from human fetal brain tissues less
than 14 weeks of age lack microglia. The cultures were
verified for purity by immunostaining using GFAP, MAP
2, and CD68 markers. Astrocyte cultures were more
than 95% pure with no evidence of microglia; neurons
were observed, but rarely [52,53].
PBMCs were separated by Histopaque (Sigma), washed
three times with PBS, and seeded in RPMI medium
supplemented with 10% fetal bovine serum (FBS) and
10% human AB plasma [54]. Monocytes were removed
by selective adherence to plastic and differentiated into
macrophages for 5 to 7 days without cytokines [54].
Jurkat, 293T, and Magi cells were obtained from the
National Institutes of Health (NIH) AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID.
Jurkat and 293T cells were maintained in RPMI-1640, and
Magi cells in DMEM with 2 mM L-glutamine supplemen-
ted with 10% FBS and 1% each of penicillin, streptomycin,
and amphotericin-B (GibcoBRL). All cultures, primary cells
and cell lines were tested for absence of Mycoplasma sps by
PCR using primers from Stratagene.
Virus packaging and infection
Full-length T-tropic HIV-1 NL4-3 [55], HIV-1 NLENG1
(NL4-3 viral DNA expressing GFP [52,56] and mutant
HIV-1 NL4-3 (D116N) and D64A defective in their inte-
grase function [57] were used as controls [52,56]. Virus
particles were packaged in 293T cells. Briefly, 17 μgo f
HIV-1 expressing plasmids were transfected in 100-mm
culture dishes (BD Falcon) using Lipofectamine 2000
(Invitrogen), as published earlier [52]. The supernatants
containing viral particles were harvested 72 h after
transfection and centrifuged at 300g for 15 minutes at 4°C
to remove cellular debris. They were treated with 5 IU/ml
RNase-free DNase (Qiagen) for 15 minutes at room
temperature (RT) and filtered through 0.22 μmm e m b r a n e
filter. Aliquots of 1.0 ml were stored at -80°C; viral titers
were determined by p24 ELISA (Zeptometrix) or infection
of Jurkat cells, as reported earlier [45]. Human MDM were
infected using M-tropic HIV-1 Ba-L strain (100 ng/ml
p24) for 2 h and washed twice with medium; the infection
was monitored for up to 21 days. Peak viral activity was
detected by p24 assay (ELISA) between 12 and 16 days
after infection. Harvested supernatants were analyzed for
chemokines and cytokines, and eventually for neurotoxic
activity. Jurkat cells were infected with NLENG1 (50 ng/ml
p24) for 2 h, washed twice with medium, and observed for
7 days. Cultures were monitored for green fluorescent
protein (GFP) expression and supernatants for viral p24.
Bioplex array and ELISA
Using a custom-made ten-plex Bioplex array (CXCL10,
IFN-γ,I L - 1 β, IL-6, IL-8, IL-17, MCP-1, macrophage
inflammatory protein (MIP)-1α, platelet-derived growth
factor (PDGF)-bb, TNF-α) according to the manufacturer’s
protocol (Bio-Rad), we analyzed cytokine and chemokine in
CSF samples (diluted 1:2 in optiMEM) from seven HIV-
ND patients and seven HIV-D patients, as well as in
supernatants from HIV-1-infected macrophages at 16 days
after infection, lymphocytes at 6 days after infection, and
HIV-1-treated astrocytes or combined TNF-α-a n dH I V - 1 -
treated astrocytes and lymphocytes at 48 h after treatment.
Uninfected culture samples were used as controls.
Briefly, undiluted culture fluids or diluted (1:2) CSF
samples (50 μl) were added to ELISA plate wells containing
analyte beads in duplicate followed by incubation for 30
minutes at RT. After washing, antibody-biotin reporter was
added and incubated for 30 minutes at RT. After washing,
streptavidin-phycoerythrin was added and incubated for 10
minutes at RT. Beadlyte readings were taken in a Luminex
reader (Austin, TX) and calculated using Bioplex software
(Bio-Rad). The sensitivity was > 5 pg/ml for each analyte.
Quantification of signals was based on the standard beads
r u ni np a r a l l e lt ot h et e s t .
TNF-α and CXCL10 were estimated in supernatants
from uninfected or HIV-1-infected macrophages and
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Biosciences) as per the manufacturer’s protocol. HFA were
seeded in 24-well plates at a density of 0.3 × 10
5 cells/well
and kept for 2 days. On the third day, cells were treated
with HIV-1 (250 ng/ml p24) and TNF-α (10 ng/ml) either
alone or in combination. In parallel, cells were treated with
IFN-γ (100 ng/ml) as a positive control. At 48 h after treat-
ment, culture supernatants were harvested for CXCL10
and TNF-α.
Cytotoxicity assay
Neuronal and astrocyte toxicity assays were done in 48-
or 96-well cell culture plates using cell viability Quanti-
Blue and lactate dehydrogenase (LDH) assays [58,59] or
flour-Jade C staining (Millipore). For direct toxicity
studies, we used equal concentrations (250 ng/ml p24
antigen) of X4-tropic HIV-1 NL4-3, mutant-HIV-1
defective in integrase function (ΔINT NL4-3), and R5-
tropic NLYU2 virus particles, for which viral DNAs were
packaged in 293T cells as described earlier [45,52]. In
parallel, H2O2 was used as a positive control; medium
was used as a negative control. Cells were cultured
overnight in optiMEM (HFN) or DMEM (HFA) and
given different treatments, as indicated in the figures.
The LDH assay was done 48 h after treatment of HFN
and HFA. Briefly, total LDH activity was calculated by
lysing the cells with 1% Triton-X for 20 minutes at 37°C.
Results were expressed as percent LDH release calculated
as follows:
% LDH ¼ OD test ðÞ =OD total ðÞ ðÞ   100
Cell viability was quantified using QuantiBlue assay
(Bioassay Systems) [45], which uses a redox nonfluorescent
dye, resuzurin; this is reduced to a highly fluorescent
product by metabolically active cells. Briefly, at the end of
treatments, 10 μl of dye was added to each culture well
containing 100 μl of medium and incubated for 3 h at 37°C.
Fluorescence in the cells was measured using Optilux black
plates (Falcon) at an excitation of 530 nm and emission at
590 nm in a fluorescence plate reader (BioTek).
In microscopic quantification, after staining with
propidium iodide (PI) (10 μg/ml) and counterstaining
for nuclei with Hoechst (1 μg/ml) for 10 minutes at 37°C,
PI uptake was estimated in cultured cells. Cells showing red
puncta were counted in five low-power fields (lpf); mean
number of PI-stained cells were calculated.
JC1 staining for mitochondrial membrane potential
was performed as described earlier [51]. In normal cells
mitochondrial membrane potential (δΨ) remains high.
Membrane permeable JC1 staining results in formation
of red colored JC1 aggregates (590 nm emission) while
during mitochondrial damage JC1 exists in monomer
form that gives green color emission (538 nm). The ratio
of 538 and 590 nm gives an estimate of mitochondrial
membrane potential (mitochondrial health). At 6 h after
treatment either with HIV alone or in combination with
cytokines, HFA were stained with JC1 dye. Briefly, 10
ug/ml JC1 (Sigma) was diluted in complete medium and
added to the cells. The δΨ was assessed following
incubation for 20 minutes in the dark at 37°C. Cellular
fluorescence was read on a florimeter (BioTek) following
excitation at 488 nm. Mitochondrial-δψ was read as the
ratio of emission at 538 nm and 590 nm. Potassium
ionophore, valinomycin (100 nM) was used as a positive
control.
RNA extraction, cDNA synthesis, and real-time PCR
Total RNA was extracted from HFA using Trizol reagent
(Gibco-BRL). This was followed by treatment with 10
units of RNase- free DNase-1 (Qiagen). RNA was further
purified using RNAeasy plus mini columns (Qiagen) [51]
and quantified by measuring absorbance at OD280.
cDNA was synthesized from 6 μg RNA using random
hexamers and Superscript II
™ reverse transcriptase
(Invitrogen) in a total volume of 60 μl at 42°C for 1 h [51].
Each real-time PCR reaction was assembled using 1 μlo f
cDNA template scaled to a 30-μl reaction (triplicate), Sybr
green master mix (Bio-Rad) with primer sets for gag gene,
gag-f (5
0-tcaatgaggaagctgcagaatggg-3
0), gag-r (5
0-tggttctctcat
ctggcctggtgc-3
0); tat gene, tat-f (5
0-gaagcatccaggaagtcagcc-3
0)
tat-r (5
0-acaaacttggcaatgaaagcaacac-3
0); nef gene, nef-f
(5
0-cctgcatggaatggatgaccctgag-3
0) and nef-r (5
0-gggccacgt
gatgaaatgctaggcg-3
0). The signals were normalized with
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
using primers GAPDH-f (5
0-catcagcaatgcctcctgcacc-3
0)
and GAPDH-r (5
0-gtgctcagtgtagcccaggatg-3
0). Serial dilu-
tions of HIV-1 pNL4-3 plasmid DNA as a template were
used to calculate primer efficiencies of all primer sets. In
parallel, negative control in which no DNA polymerase
was present and in another control no cDNA template
was present, were used. Reactions were run on a CFX96
real-time PCR system (Bio-RAD). Data were collected and
analyzed using Bio-RAD CFX Manager Software v 1.1.
Authentic PCR amplification was validated by examining
whether any non-specific amplification occurs from RNA.
Ct values were calculated for each gene and normalized
relative to GAPDH expression. Fold expression from
untreated control or ΔΔCt was calculated using the Paffafl
method as reported earlier [60].
Immunofluorescence and flow cytometry
HFA and HFN were seeded on 8-chambered slides
(LabTek) coated with poly-D-lysine (20 μg/ml) (Sigma),
then cultured for 4 days in complete medium. After various
treatments, cells were processed for immunofluorescence
as described earlier [52,53]. Briefly, cells were fixed with 2%
paraformaldehyde in buffered saline for 15 minutes. After
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containing 0.01 M glycine in PBS for 11 minutes, stained
overnight with monoclonal anti-GFAP (1:400) or MAP-2
(1/400) (both from Sigma), and labeled with anti-mouse
alexa-569 conjugate antibody (1:500). For CXCR3 or
CXCR4 receptors, cultures were immunostained overnight
at 4°C using human anti-CXCR3 (1:400) (R&D) and labeled
with anti-mouse Alexa 488 (1:500) for 1 h at RT, then
stained overnight with human anti-CXCR4-PE conjugated
antibody (1 μg/ml) at 4°C (eBiosciences). For expression
of IFN-γ, astrocytes treated either alone with TNF-α
(10 ng/ml) or in combination with HIV-1 (250 ng/ml) for
48 h were immunostained with anti human IFN-γ Alexa
488 (eBiosciences) at 4°C overnight. After IFN-γ immunos-
taining, astrocytes were co-immunostained for GFAP
marker as described above. To stain damaged neurons,
immunostained cells were treated with 0.006% KMnO4
for 5 minutes, then stained with 0.0001% Fluoro-Jade C
(Millipore). Cells were counterstained for nuclei with
1 μg/ml Hoechst (Sigma) and counted for cell death
using a fluorescence microscope (Nikon). Images were
captured with a digital camera (Nikon).
CXCR4 expression on HFA and HFN were monitored
using flowcytometry. HFA and HFN were grown in 6-
well plates for a week. After mild trypsinization for 60
sec to avoid removal of surface receptors, trypsin was
neutralized with 10% FBS and cells were washed. The
cells were resuspended in 1% BSA containing PBS, then
stained using appropriate antibodies conjugated with PE
and the isotype control antibody for 1 h at 4°C; 100,000
cells per sample were acquired and analyzed using flow
cytometry (Beckman Coulter).
Cell migration assay
Using a modified Boyden chamber (NeuroProbe) method,
we monitored the chemotactic activity of supernatants
collected from astrocytes treated with HIV-1, HIV-1 plus
bryostatin, or supernatants from HIV-1 infected macro-
phages. Briefly, 30 μl of each supernatant in quadruplicate
was used in the lower chamber, separated by a polycarbon-
ate membrane (5 μm pore size) in a 96-well culture plate.
Activated PBMCs were washed twice in optiMEM. We
seeded 50,000 cells per well in a 50-μl volume on top of the
membrane. We incubated the culture plate at 37°C for 90
minutes. Cells that had migrated across the membrane in
the lower chamber were recovered by centrifugation at
1,000 g for 2 minutes and transferred to BD-Optilux black
plates. In parallel, 2-fold serial dilutions of PBMCs were
used to make a standard curve. To estimate migrated cells
across the membrane, we established a plate-based staining
procedure, staining harvested cells with 0.2 μM ethidium
bromide in 10 mM Tris chloride and 0.1% Triton × 100
for 10 minutes. Fluorescence was read at an excitation of
530/30 nm and emission at 590/30 nm using a Synergy2
plate reader (BioTek). The number of migrated cells was
determined by standard curve.
Statistics
Results are represented as mean ± standard error of the
mean (SEM) for each bar set plotted using Sigma plot
v8.0 with associated P-values for each treatment group
compared to its control. Statistical analysis was done
using Origin 6.1 software. Significance between two
groups was calculated using the two-tailed Student’s t-test.
P < 0.05 was considered significant. For patients’ CSF data,
results were further validated using the nonparametric
two-tailed Mann-Whitney U test.
Results
Signatory proinflammatory chemokines and cytokines in
HIV-1-infected demented patients
We investigated the proinflammatory response in the
CSF of HIV-D and HIV-ND patients using Bioplex array.
CSF samples were profiled for cytokines and chemokines
using a custom-made 10-plex Bioplex array. That analysis
showed that five signatory chemokines/cytokines (IL-6,
IFN-γ, PDGF-bb, CXCL-10, and MCP-1) were upregulated
in HIV-D patients, but not HIV-ND patients (Figure 1).
Other proinflammatory molecules tested (IL-8, IL-1β,
IL-17, MIP-1α) were expressed at basal levels in both
groups (data not shown). In the CSF of HIV-D patients
as compared to HIV-ND patients, signaling IL-6, IFN-γ
and PDGF-bb cytokines were respectively upregulated
5.5-fold (28.8 ± 5.4 pg/ml), 2.2-fold (56.4 ± 5.0 pg/ml), and
2.4-fold (212.7 ± 36 pg/ml) (Figure 1A-C, inset). Similarly
CXCL10 and MCP-1 chemokines were increased 4.6-fold
(17.3 ± 3.2 ng/ml) and 3.4-fold (949 ± 52 ng/ml)
(Figure 1D, E) in HIV-D. To elucidate the source of the
proinflammatory cytokines/chemokines, we investigated
HIV-1 infection in astrocytes, lymphocytes, and macro-
phages, given their roles in neurological complications. Of
note, TNF-α was undetectable in CSF but was found in
HIV-1 infected macrophages.
HIV-1 infection in macrophages and lymphocytes
provokes CXCL10, MCP-1, and TNF-α
Primary human macrophages and lymphocytes were
either infected with M-tropic HIV-1 (Ba-L strain or
NLENYU2), T-tropic NLENG1, or left uninfected.
Culture supernatants from infected and uninfected
macrophages were collected on day 14 and 16 after
infection and from lymphocytes on day 4. We monitored
infection in lymphocytes by fluorescence microscopy
and in macrophages by immunostaining for p24. At day
16, immunostaining demonstrated high expression of
viral p24 antigen in HIV-1 infected, but not uninfected
macrophages (Figure 2A, upper panel). Using viral p24
antigen ELISA, a viral peak was detected between day 14
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shown). Interestingly, the proinflammatory response of
supernatants from HIV-1-infected macrophages on day
16 after infection showed marked increases in CXCL10,
MCP-1, and TNF-α by Bioplex array (Figure 2A, lower
panels), while other cytokines and chemokines were not
significantly changed (data not shown). CXCL10 and
MCP-1 levels in HIV-1- infected macrophages were
most prominent (Figure 2A).
Given the infiltration of T-cells, albeit less pronounced
than monocytes or macrophages in HIV-infected brains,
we further examined the proinflammatory response of
lymphocytes to HIV-1 and TNF-α. HIV-1 infection as
seen by GFP expression occurred in infected but not
uninfected Jurkat cells after 48 h (Figure 2B, upper
panel). At 48 h after treatment with either HIV-1 alone
or in combination with TNF-α, Jurkat cells showed
approximately 10-fold induction in CXCL10 levels as
compared to HIV-1-infected or normal controls
(Figure 2B). However, the proinflammatory response of
Jurkat cells to combined HIV-1 and TNF-α treatment
was much less pronounced than that in infected macro-
phages (Figure 2A and B). Overall, HIV-1 distinctly
provoked increases in CXCL10 in macrophages, and
lymphocytes.
TNF-α and HIV-1 induce a proinflammatory response in
astrocytes similar to that in HIV-D patients
Elevation of TNF-α, which is secreted from HIV-1-
infected macrophages or microglia, has been widely
shown to occur in response to hepatitis C virus (HCV)
co-infection or methamphetamine abuse in HIV-1 infec-
tion settings [39,61-65]. In this study, TNF-α was un-
detectable in CSF samples, but was found in culture
supernatants of HIV-1 infected macrophages by Bioplex
array. We investigated the possible role of TNF-α, either
alone or in combination with HIV-1, in provoking a
proinflammatory cascade in astrocytes.
We treated HFA with HIV-1 (250 ng/ml p24), TNF-α
(10 ng/ml), or a combination of these two, for 48 h, then
monitored the cytokine or chemokine response using a
Bioplex array. Given the presence of M-tropic and T-tropic
viruses in the brains of HIV-1 patients [2], we tested stocks
of different doses of M-tropic and T-tropic HIV-1 prepared
in HEK-293 cells (free of proinflammatory products). We
found that a concentration of 250 ng/ml was effective in
toxicity studies on HFA (unpublished), and used this in
further studies. Interestingly, co-treatment with HIV-1 and
TNF-α showed a robust proinflammatory response similar
to that observed in HIV-D patients, but TNF-α alone was
ineffective (Figure 3A). Compared to controls, the levels of
Figure 1 Analysis of cytokines and chemokines by Bioplex array on CSF samples (A-C) cytokines and (D, E), chemokines in CSF
samples from HIV-D and HIV-ND patients. CSF samples were diluted 1:2 and 50 μl of each sample was used in the Bioplex array. Insets show
mean elevated levels of (A) IL-6 (5.5- fold), (B) IFN-γ (2.2- fold), (C) PDGF-β (3.7- fold), (D) CXCL10 (4.6- fold), and (E) MCP-1 (3.4- fold) in CSF from
HIV-D patients as compared to levels in HIV-ND patients. CSF, cerebrospinal fluid; HIV-D, HIV-demented; HIV-ND, HIV-nondemented; PGDF,
platelet-derived growth factor; MCP, monocyte chemotactic protein.
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IL-1β, 2-fold; IL-6, 11.2-fold; IL-17, 2.2-fold; MIP-1α,
1.5-fold; PDGF-bb, 1.4-fold; and IFN-γ, 2-fold (Figure 3A,
left panel). In astrocytes, co-treatment with HIV-1 and
TNF-α i n d u c e dI L - 8a n dM C P - 1( F i g u r e3 Ar i g h tp a n e l )
similar to IFN-γ. Remarkably, CXCL10 was profoundly
upregulated (> 1,000-fold) in astrocytes after co-treatment
with TNF-α and either wild-type (wt) or mutant (defective
in integrase function) HIV-1 particles (Figure 3B, C). This
finding, validated by ELISA, suggests that HIV-1 without
replication can induce CXCL10 production in bystander
cells (Figure 3C). Treatment with IFN-γ, a known inducer
of CXCL10, was used as a positive control. Interestingly,
HIV-1 and TNF-α treated astrocytes showed synergistic
upregulation of CXCL10 production similar to that of
IFN-γ (Figure 3C). Overall, TNF-α in combination with
HIV-1 distinctly provoked an increase in CXCL10 in
astrocytes. To further investigate the significance of
TNF-α and HIV-1, we studied their effect on neurons
and astrocytes.
Figure 2 HIV-1-infected macrophages and lymphocytes induced CXCL10, MCP-1, and TNF-α. (A) Primary human macrophages were mock-
infected or infected with HIV-1 B-aL (100 ng/ml p24). Supernatants collected on the day 14 and 16 post-infection were analyzed for cytokine/
chemokine profile. Upper panel shows immunostaining for viral p24 antigen (red) in HIV-1-infected but not -uninfected (control) macrophages at
16 days post infection. Nuclei were stained with DAPI (blue). (B) Jurkat cells were co-treated with TNF-α (10 ng/ml) and either wild-type HIV-1
NLENG1 (wt) or integrase-defective mutant HIV-1 (M) particles for 48 h. Supernatants collected at 48 h after treatment were analyzed for CXCL10
production by ELISA. Upper panel shows GFP expression in HIV-1-infected but not uninfected Jurkat cells. DAPI, 4',6-diamidino-2-phenylindole;
MCP, monocyte chemotactic protein; GFP, green fluorescent protein.
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not in neurons
To study the effect of TNF-α in brain injury, we investi-
gated its impact on HIV-1-induced glial toxicity. Having
found that both M-tropic and T-tropic HIV-1 were
equally cytotoxic to astrocytes (Mehla and Chauhan, 2011,
unpublished), we monitored the toxicity profile of HFA at
48 h after treatment with HIV-1 NL4-3 virus particles
(50 and 250 ng/ml p24) and TNF-α (0.1-10 ng/ml).
Initially, we used an LDH release assay on culture super-
natants to monitor cytotoxicity, then later confirmed our
results by propidium iodide uptake, Trypan blue, or
MTT assay. Interestingly, co-treatment of astrocytes with
TNF-α and HIV-1 dose-dependently caused exaggerated
toxicity in LDH release (Figure 4A) and Trypan blue
uptake assays (Figure 4B).
TNF-α activates HIV-1 transcription via activation of
NF-kB in lymphocytes and macrophages, and conse-
quently provokes a proinflammatory response [66-68].
Thus, TNF-α may increase viral protein synthesis and
consequently exaggerate the toxic response by astrocytes,
resulting in neurotoxicity. To rule out exaggerated toxicity,
if any, by increased viral replication in astrocytes as
compared to that in neurons, we infected HFA with HIV-
NLENG1 virus, which expresses GFP [45,56,60]. This
allows monitoring of HIV-1 gene expression in real time.
HFA, in parallel with Jurkat cells (positive control), were
infected with HIV-1 and treated with TNF-α; 48 h later
we monitored GFP expression. TNF-α treatment either
pre- or post-infection did not cause an increase in GFP
expression and remained undetectable in HIV-1 infected
HFA, while Jurkat cells showed substantial increases
Figure 3 HIV-1 and TNF-α induced CXCL10 production in astrocytes. (A) HFA were treated with TNF-α (10 ng/ml) in combination with equal
concentrations (250 ng/ml p24) of either wild-type HIV-1 NL4-3 (wt) or integrase-defective mutant HIV-1 (M) for 24 h. Cultures were washed once
and replaced with fresh medium. Supernatants collected at 48 h after treatment were analyzed for cytokines/chemokines by Bioplex array. (A)
IFN-γ, IL-8, MCP-1, PDGF, and (B) CXCL10 were elevated in culture supernatants collected from TNF-α- and HIV-1-treated HFA. (B-C) CXCL10
production from HFA was confirmed by quantitative ELISA. HFA, human fetal astrocytes; MCP, monocyte chemotactic protein; PDGF, platelet-
derived growth factor.
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(Figure 5A, B).
To determine whether HIV-1 gene expression occurs
in HFA without GFP expression, we co-treated HFA
with HIV-1 and TNF-α for 48 h and monitored viral
early (tat and nef)- and late (gag)-mRNA transcripts
using reverse-transcription-coupled real-time PCR. In
parallel, we used lymphocytes as positive controls. Un-
like HIV-1 susceptible lymphocytic cells, viral transcripts
in HFA remained at undetectable or basal levels after
treatment with TNF-α (Figure 5C), indicating that TNF-
α-synergized HIV-1-induced toxicity in astrocytes was
independent of productive HIV-1 infection, rather than
being directly induced by viral particles. In parallel, we
used equal concentrations of HIV-1 mutant virus that
was defective in integrase function (incapable of pro-
ductive infection, ΔINT) as an additional control
(Figure 5C). Mutant HIV-1 gave results similar to those
obtained with wt virus, thus reinstating the viral
envelope-mediated signaling event. To confirm this, we
used AMD3100, a CXCR4 receptor blocker, to reverse
HIV-1-induced toxicity. HFA showed high expression of
CXCR4 (Figure 6A, inset) and AMD3100 dose depend-
ently attenuated HIV-1-induced toxicity (Figure 6A).
Intriguingly, AMD3100 did not attenuate HIV-1+TNF-
α-induced toxicity in HFA (Figure 6B), suggesting induction
of a different toxic pathway in astrocytes.
Subsequently, we tested the effect of HIV-1 particles
in combination with TNF-α on primary HFN. The HFN
cultures grown for two months were used in the experi-
ments. Co-treatment of HFN with TNF-α and HIV-1
showed no enhanced toxicity and, indeed, suppressed
neurotoxicity (Figure 7A), suggesting some intracellular
neuroprotective programming that needs to be investi-
gated further.
HIV-1 with CXCL10, but not TNF-α, synergistically induced
neuronal toxicity
It has been shown that elevated levels of CXCL10 and
MCP-1 in the CSF of HIV-D patients are chemo-
attractants for lymphocytes and monocytes or macro-
phages, resulting in an exaggerated neuroinflammatory
response [8,14]. We found that HIV-1 and TNF-α to-
gether induced release of various chemokines, including
CXCL10, from astrocytes and lymphocytes. Also, HIV-D
CSF showed elevated CXCL10 levels. We investigated
whether CXCL10 in combination with HIV-1 particles
compromise the survival of neurons. Treatment of neurons
with HIV-1 (250 ng/ml p24) and CXCL10 (100 ng/ml) for
48 h showed exaggerated toxicity in an LDH release assay
(Figure 7B). We also did FJC staining for dying neurons
and immunostaining for astrocytes using anti-GFAP. FJC
stains degenerating neurons irrespective of the type of
insult. After co-treatment of mixed neuronal cultures
with CXCL10 and HIV-1, increased expression of GFAP
positivity was coupled with neuronal damage (Figure 7C).
This suggests that TNF-α and HIV-1 deregulate astrocyte
function more severely than does HIV alone (Figure 2)
and eventually compromises neuronal functions via
CXCL10 (Figure 7B, C). However, TNF-α may also induce
neuroprotection. A possibly similar neuroprotective effect
was observed in our mixed neuronal cultures using TNF-α
and HIV-1 insult (Figure 7A). Nottet et al. [13] found that
astrocytes dampen TNF-α-induced neurotoxicity when co-
cultured with HIV-1-infected macrophages and neurons.
However, our neuronal cultures lacked microglia and
macrophage phenotypes and may not have reflected all the
consequences of the in vivo situation. Together, our results
Figure 4 TNF-α synergized HIV-1-induced toxicity in astrocytes.
(A) TNF-α with HIV-1 increased toxicity on astrocytes (HFA). LDH
release was estimated in culture supernatants from HFA after
treatment with increasing concentrations of TNF-α (0–10 ng/ml) and
HIV-1 NL4-3 (50 ng/ml, 250 ng/ml p24 concentrations) or TNF-α
alone for 48 h. Controls were left untreated (negative control). H2O2
was used as a positive control (P < 0.05). (B) HFA were treated with
HIV-1 alone (250 ng/ml) or in combination with TNF-α (10 ng/ml). At
48 h after treatment, cell death was monitored by Trypan blue dye
exclusion. Untreated HFA served as a negative control. Results were
plotted as mean ± standard error of the mean (SEM) after counting
20 high-power fields for each treatment (n = 3). HFA, human fetal
astrocytes; LDH, lactate dehyrdrogenase.
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not TNF-α, induces neuronal toxicity.
Ablation of CXCL10 and HIV-1-induced neurotoxicity by
the mitogen-activated protein kinase inhibitor and PKC
activator
To investigate the mechanism of CXCL10- and HIV-1-
induced neurotoxicity, we monitored HFN for expres-
sion of CXCR3 and CXCR4, which has been reported to
occur in various cells, including activated lymphocytes,
monocytes, and endothelial cells [37,69]. HFN showed
expression of CXCR4, a co-receptor for HIV-1, and of
CXCR3, a receptor for CXCL10 (Figure 8A). CXCR4 is
the receptor that engages HIV-1 gp120 and Tat proteins
on the cell surface, resulting in transduction of intracellular
signals. CXCR4 alone is not responsible for transducing the
neurotoxic signal, but may trigger a proinflammatory
response. Binding of CXCL10 to CXCR3 receptors
transduces the signaling cascade by activating the
mitogen-activated protein kinase (MAPK) pathway [70].
To investigate the involvement of CXCL10-CXCR3
signaling in HIV-1-induced neuronal toxicity, we
pretreated neurons with 5 μg/ml of CXCR3 blocking anti-
body (R&D systems) or MAPK p38 inhibitor (SB203580)
and monitored neurotoxicity by LDH release 24 h later.
To investigate the role of the CXCR4 receptor in HIV-1-
induced neurotoxicity, we targeted the PKC pathway
(bryostatin), which we and others have shown to be
involved in CXCR4 regulation [43-45]. Protein kinase
activation by bryostatin has been shown to decrease
expression of CXCR4 on lymphocytes and result in
reduced HIV-1 infection [45]. To find the working nontoxic
concentration of bryostatin, we initially did a dose response
test on HFA using different concentrations of bryostatin
(1 to 100 nM). No toxic effects were seen by LDH assay
(Figure 8B). Blocking either CXCR3 receptors or MAPK
signaling annihilated HIV-1 and CXCL10-induced
neurotoxicity (Figure 8C) indicating involvement of the
Figure 5 Effect of TNF-α on HIV-1 transcript expression in infected astrocytes. HFA and Jurkat cells (positive control) were infected with
HIV-1 NLENG1 (50 ng/ml) (YFP-expressing HIV-1 to track infection in live cells) and treated with TNF-α (10 ng/ml) or left untreated. (A) HIV-1
infection was assessed by the number of GFP-expressing cells. Representative pictures of Jurkat and HFA showing GFP-positive cells. (B)
Quantification of HIV-1 infection was done by counting GFP-positive cells in 10 random fields and plotted as mean ± standard error of the mean
(SEM). (C) HFA and Jurkat cells were treated with TNF-α (10 ng/ml) in combination with either HIV-1 wt or HIV-1 integrase- defective mutant
(ΔINT) as a negative control for viral replication. Cells were harvested after 48 h of treatment for total RNA and monitored for early and late viral
mRNA transcripts (tat, nef, and gag) using reverse-transcription coupled real-time PCR. UD = undetectable (n = 2). HFA, human fetal astrocytes;
GFP, green fluorescent protein; wt, wild type.
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at a 25 nM concentration of bryostatin profoundly
suppressed both HIV-1- and CXCL10 + HIV-1-induced
neurotoxicity (Figure 8C, D).
Thus, to determine whether CXCR4 and CXCR3
receptors are involved in transducing toxicity signals, we
immunostained mixed neuronal cultures for GFAP, then
stained them with FJC staining for neuronal death after
combined HIV-1 and CXCL10 insult (Figures 7, 8).
HIV-1-treated mixed neuronal cultures showed enhanced
expression of astrocytic activation marker; in combination
with CXCL10, it showed increased neuronal damage
(Figures 7, 8). These results indicate that CXCL10-CXCR3
intersects with the HIV-CXCR4 pathway in neurons to
enhance toxicity. Thus far, blocking either MAPK signaling
or CXCR3 and CXCR4 receptors resulted in neuroprotec-
tion against HIV-1 or combined insult with HIV-1 and
CXCL10, suggesting that the PKC activator bryostatin has
therapeutic potential (Figure 8C, D).
Bryostatin suppressed CXCL10 and HIV-1 induced
chemotaxis of PBMCs
CXCR3 expression on neurons in HIV-1-infected brains
has been reported [71,72]. Moreover, induction of
CXCL10 in HIV-1-infected patients with neurological
complications has been demonstrated [7,9,33,35,71].
Given that migration of monocytes or macrophages and
lymphocytes occurs in the brains of HIV-1-infected
patients and results in neuroinflammation and neurotox-
icity, we investigated whether CXCL-10 and HIV-1 confer
any effect on migration of PBMC. To examine migration,
we co-treated astrocytes with HIV-1 and CXCL10 in
serum-free medium for 48 h. In parallel, we co-treated
mixed neuronal cultures for 24 h with HIV-1 and CXCL10
or left them untreated (medium control). Cultures were
washed to deplete residual CXCL-10 and HIV-1 particles
and fresh medium was added. The conditioned superna-
tants were collected 48 h later and monitored for chemo-
tactic potential for activated PBMC in a migration assay
using a modified Boyden chamber (NeuroProbe). In parallel,
we used CXCL-10 (100 ng/ml) or MCP-1 (50 ng/ml) as
positive controls and mock-treated supernatants from HFA
or HFN as negative controls. The supernatants from
CXCL10 and HIV-1-co-treated HFA or HFN cultures
showed profound increases in activated PBMC migration
(Figure 9A), indicating that proinflammatory products,
including CXCL10, are crucial in chemotaxis.
Given that bryostatin protected neurons against HIV-1
and CXCL10 toxicity, we investigated whether this PKC
activator confers an inhibitory effect on CXCL10-induced
chemotaxis. We co-treated HFA with HIV-1 and CXCL10,
then with either bryostatin (25 nM) or vehicle control
( d i m e t h y ls u l f o x i d e ,D M S O ) .T he supernatants, which were
free of added HIV+CXCL-10 and bryostatin, were collected
48 h later and used in chemotaxis assays. The supernatants
from bryostatin-treated CXCL10 and HIV-1 conditioned
HFA, but not those from CXCL10 and HIV-1 conditioned
supernatants, showed profound reductions in PBMC
chemotaxis (Figure 9B), suggesting that bryostatin has
significant therapeutic potential against HIV-1-induced
Figure 6 CXCR4 blocker attenuated HIV-1 but not combined
TNF-α and HIV-1-induced astrocyte toxicity. (A) HFA pretreated
with CXCR4 blocker (AMD3100) (0.5 or 5.0 μM) were given HIV-1
treatment; 48 h later, LDH release was estimated in cell supernatants
(P < 0.05). Inset shows overlay histogram of CXCR4 receptor
expression in HFA after treatment with TNF-α for 16 h analyzed by
flow cytometry, with the percentage of cell population shown
relative to isotype control. (B) HFA were pretreated with AMD3100
(CXCR4 blocker) for 30 minutes at the indicated concentrations, then
treated with a combination of HIV-1 (250 ng/ml) and TNF-α (10 ng/ml)
and monitored for LDH release as before. HFA, human fetal astrocytes;
LDH, lactate dehyrdrogenase.
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that the bryostatin-mediated effect occurs by regulating
cytokines and chemokines in astrocytes, but not directly at
PBMC levels, since bryostatin was not present during the
migration assays. Detailed investigations to elucidate the
mechanism of bryostatin in neuroprotection and chemo-
taxis are in progress.
Discussion
Gliosis and infiltration of activated monocytes, macro-
phages and lymphocytes in the brain compartment are
important causes of inflammation and neurodegenera-
tion in chronic HIV-1-infected patients [9,73,74]. Gliosis
is characterized by the release of several cytokines and
chemokines from activated glial cells both as astrocytes
and microglia. TNF-α and other proinflammatory cyto-
kines in the CSF and brain tissues of HIV-D patients
correlate with the severity of HIV-1 disease progression
[9,14,25,75,76]. In vivo and in vitro studies, including
this one, have shown CXCL10 production from astro-
cytes following expression of gp120 or treatment with
combination of TNF-α and IFN-γ with HIV-1 [21].
Second to microglia and macrophages, astrocytes are
thought to be a source of the proinflammatory response
in HIV-1 infection [77-79]. Activated T-cells in the brain
also participate in neuroinflammation. However, upon
T-cell depletion in the late stages of HIV-1 infection,
monocytes and macrophages predominate in the
migrated cell population in HIV-1 infected brains.
Using a Bioplex array on CSF, signatory cytokines and
chemokines were seen; CXCL10 and MCP-1 were
characteristic in HIV-D patients. On further in vitro
investigation of astrocytes, macrophages, and lymphocytes,
we found that CXCL10 was induced by HIV-1 infection or
treatment with TNF-α or IFN-γ, suggesting that myeloid
and lymphoid cell populations are key players in CXCL10.
Figure 7 CXCL10, but not TNF-α, synergized HIV-1-induced neuronal toxicity. (A) LDH activity was estimated in supernatants from HFN
treated with HIV-1 alone or in combination with TNF-α.H 2O2 was used as a positive control. (B) Mixed neuronal cultures (HFN) were co-treated
with HIV-1 (250 ng/ml p24 concentration) and CXCL10 for 24 h. LDH release was estimated on cell supernatants. (C) HIV-1 and CXCL10 co-treated
HFN were immunostained for GFAP (red), then counterstained with FJC (green), which stains dead neurons. Nuclear staining was done with DAPI
(blue). LDH, lactate dehyrdrogenase; HFN, human fetal neurons; GFAP, glial fibrillary acidic protein; FJC, fluoro-jade C; DAPI, 4',6-diamidino-2-
phenylindole.
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Similar to our earlier observations [52], HIV-1 infection in
astrocytes was not observed within 48 h. Irrespective of the
lack of productive HIV-1 infection, co-treatment of astro-
cytes with TNF-α and HIV-1 particles for 48 h showed
upregulation of CXCL10 expression. Induction of CXCL10
in astrocytes could be an indirect effect of upregulation of
other proinflammatory products, including IFN-γ.H o w -
ever, induction of CXCL10 in astrocytes by HIV-1 and
TNF-α could be independent of IFN-γ. Although secretion
of IFN-γ by activated or HIV-1 infected T-cells has been
reported, no evidence on astrocytes has been documented.
Recently, investigations of reovirus-infected animal brains
demonstrated expression of IFN-γ in astrocytes [80]. Astro-
cytes under ischemic conditions also showed extracellular
but not intracellular IFN-γ expression [81]. Similarly, in our
current study, astrocyte cultures, on co-treatment with
TNF-α and HIV-1, showed extracellular (Figure 3A) but
not intracellular IFN-γ expression (data not shown). Over-
estimation of IFN-γ expression could be due to variation in
the multiplex assay. Intracellular absence of IFN-γ in our
study could be a consequence of the antibody used for de-
tection after cell fixation; this needs further investigation.
An earlier study on transgenic mice expressing HIV-1
gp120 under GFAP promoter did not detect IFN-γ in
astrocytes [21]. It can be argued that ectopic application
of HIV particles to astrocytes provokes intracellular
signaling that is different from intracellularly expressed
HIV-1 gp120 protein.
CXCL10 signaling is important in other brain pathologies,
including Alzheimer’s disease and multiple sclerosis [30].
Astrocytes expressing CXCL10 are commonly associated
with senile plaques [26]. TNF-α and HIV-1 induced toxicity
in HFA, but unexpectedly reduced toxicity in HFN cultures.
In earlier reports [82-84], TNF-α-mediated neurotoxicity
was dampened by the presence of astrocytes either neutral-
izing the effect or producing the anti-inflammatory product
IL-10. In our mixed neuronal cultures, the presence of
astrocytes in the absence of microglia or macrophages
might have conferred effects similar to those in the preced-
ing studies. Although there is limited evidence of TNF-α
production in HIV-infected brains, it has been suggested
Figure 8 PKC activator (bryostatin) and MAPK inhibitor protected against CXCL10- and HIV-1-induced neurotoxicity. (A) HFN cultures
were immunostained for CXCR3 (green) and CXCR4-PE (red), then counterstained with DAPI (n = 3). (B) Dose response of bryostatin for toxicity;
HFA cultures were treated with increasing concentrations of bryostatin (0 to 100 nM). LDH was estimated in supernatants 48 h post-treatment.
(C-D) HFN were pretreated with bryostatin (25 nM), CXCR3 blocking monoclonal antibody (5 μg/ml), or MAPK inhibitor SB203580 (5 μM), then
insulted with a combination of (C) HIV-1 and CXCL10 or (D) HIV-1 alone. At 24 h post-treatment, LDH activity was monitored in supernatants.
H2O2 was used as a positive control (n = 2). PKC, protein kinase C; MAPK, mitogen-activated protein kinase; HFN, human fetal neurons; DAPI, 4',6-
diamidino-2-phenylindole; HFA, human fetal astrocytes; LDH, lactate dehydrogenase.
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lipopolysaccharide (LPS). In our Bioplex array on CSF
samples, no evidence of secretory TNF-α production was
seen. However, such evidence was seen in the supernatants
from HIV-1-infected macrophages. Nevertheless, TNF-α
production may occur in situations such as drug abuse and
the co-occurrence of other opportunistic infections with
HIV-1 [85].
In addition to TNF-α, IL-6, which is also considered to
be neurotoxic, is induced by HIV-1 gp120 [17]. However,
IL-6 at the levels we detected in HIV-D patients’ CSF did
not induce toxicity in HFA and HFN (Figure 10). Although
IFN-γ and MCP-1 were also elevated in the CSF of HIV-D
patients and in vitro in our studies, they failed, alone or in
combination with IL-6, to induce neuroglial toxicity
(Figure 10).
Interestingly, in an earlier study TNF-α-induced-
CXCL10 expression stimulated HIV-1 replication in
susceptible cells, including MDM and peripheral blood
lymphocytes [86]. These cells migrate to the CNS
compartment and contribute to elevated levels of inflam-
matory cytokines and viral proteins, which are HIV-1-
derived toxic products. CSF from HIV-D patients, as
compared to that from HIV-ND patients, showed a
nearly 4-fold increase in CXCL10, indicating the import-
ance of CXCL10 in the CNS. The CSF of two HIV-ND
patients also had elevated CXCL10, indicating that these
patients had ongoing viral activity that could progress to
dementia. Thus, antiretroviral treatment is important in
discouraging severe neurological complications; however,
residual proinflammatory response in successfully trea-
ted HIV-infected patients nevertheless leads to minor
cognitive impairment. In our study, CXCL10 was also
induced at high levels in HIV-1-infected lymphocytes
and macrophages and in HIV-1 + TNF-α-treated HFA.
This indicates that neurons, during T-cell and macrophage
infiltration in the brains of HAD patients, encounter
localized concentrations of CXCL10 that exceed CSF levels.
Moreover, a recent study has reported persistence of
CXCL10 in the plasma of HIV-1 patients treated with anti-
viral therapy, suggesting that immune activation was still
active during treatment [87]; this phenomenon may be
more active in brains where antiviral drugs are less available.
In addition to CXCL10, we found that MCP-1, a mediator
of transmigration of monocytes or macrophages into the
brain, was present in high levels both in vivo and in vitro.
Treatment of neurons with CXCL10 and HIV-1 had a
synergistic effect on neuronal toxicity. Also, supernatants
from CXCL10- and HIV-1-treated astrocytes had a pro-
found effect on the migration of activated PBMC. Similarly,
CXCL10 has been shown to cause neuronal damage in
animal models [21,88,89]. CXCL10 is a potent chemokine
that induces chemotaxis of immune cells (T-cells, mono-
cytes/macrophages, NK cells, and plasmacytoid dendritic
cells) [14]. In general, CXCL10 imparts its effects through
CXCR3 receptors on target cells [22,90-92]. Chemokine
CXCR3 receptors are abundantly distributed on neurons
and neuronal processes in various HIV-1-susceptible
cortical and subcortical brain regions [14,21,32]. In
Figure 9 PKC activator inhibited HIV-1- and CXCL10- induced
chemotaxis of PBMC. Activated PBMC were isolated from human
blood donors and cultured in PHA and IL-2 for 2 days. Chemotaxis
of PBMCs by culture supernatants collected from HIV-1 and CXCL10-
treated HFA were done using a modified Boyden chamber. (A)
Culture supernatants from HFA after 48 h of treatment with HIV-1 or
a combination of HIV and CXCL10 were used in chemotaxis assays.
CXCL10 (100 ng/ml) was used as a positive control (first bar). (B)
HFA were pretreated with bryostatin (25 nM) for 30 minutes, then
treated with a combination of HIV-1 (250 ng/ml p24) and CXCL10
(10 ng/ml) for 48 h. Culture supernatants were used in chemotaxis
of PBMC. In parallel, supernatants from HFN cultures treated with a
combination of HIV-1 and TNF-α were also used (P < 0.05) (n = 2).
PKC, protein kinase C; PBMC, peripheral blood mononuclear cells;
HFA, human fetal astrocytes; HFN, human fetal neurons.
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lated without inducing harmful consequences [93,94].
However, elevated CXCL10 expression in neurons in re-
sponse to brain injury resulted in activation and migration
of microglia to injury sites. After ablating CXCR3 (knock-
out mice), which is a receptor for CXCL10, axon trimming
was impeded [95,96]. To corroborate that CXCL10 signal-
i n gh a dt o x i ce f f e c t so nn e u r o n s ,w ed e m o n s t r a t e dC X C R 3
receptors in human neuronal cultures (Figure 8). Blocking
the CXCR3 receptors on neurons abolished the neuronal
toxicity induced by HIV-1 and CXCL10. Further, a
combination of HIV-1 and CXCL10 showed selective
toxicity in neurons; this toxicity was abrogated by
treatment with MAPK inhibitor. In addition, neurotox-
icity induced by HIV-1 and CXCL10 or by HIV-1 alone
was profoundly decreased by treatment with the PKC
activator, bryostatin. Treatment with bryostatin is
reported to confer pleotropic effects on neuro-glial cells,
and is currently being tested in a phase II clinical trial for
treatment against Alzheimer’s disease (http://www.brni.org/
scientific_research/clinical_trials.aspx). Bryostatin has been
shown to confer neuroprotection on various disease
models, not only enhancing learning, but also promoting
nerve growth-factor-dependent outgrowth of neurites
via PKC-ε [49,97,98]. Earlier, we found [45] that bryosta-
tin treatment suppressed the expression of CXCR4 in
Figure 10 Combined effect of IL-6, IFN-γ, and MCP-1 on neuroglial (HFN and HFA) damage. (A, B) HFA and (D, E) HFN were treated with
different doses of IL-6 (75 to 750 pg/ml) or IFN-γ (100 to 1,000 pg/ml) either alone or together (150 pg/ml IL-6 and 200 pg/ml IFN-γ). Toxicity was
determined by LDH assay at 48 h after treatment. (C) IL-6 and IFN-γ, alone or in combination with MCP-1 (5 ng/ml), were tested in modulating
mitochondrial membrane potential in HIV-1-treated astrocytes after 12 h of treatment. (F) Dose response of MCP-1 (1–25 ng/ml) in inducing
neuroglial toxicity. (G, H), Effect of IL-6 and IFN-γ in combinations with HIV-1 on the (G) toxicity profile (LDH) and (H) viability (MTT/QuantiBlue) of
neurons at 48 h after treatment. Effects of IL-6, IFN-γ, and MCP-1 in combination with HIV-1 in modulating (I) toxicity (LDH) and (J) viability
(QuantiBlue) at 48 h post-treatment in neurons. MCP, monocyte chemotactic protein; HFN, human fetal neurons; HFA, human fetal astrocytes;
LDH, lactate dehydrogenase.
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that were similar to observations reported in an earlier
study [99]. We have also reported that bryostatin
inhibits HIV-1 infection independent of viral receptors.
In the current study, bryostatin also decreased the
chemotactic activity of supernatants collected from
astrocytes after co-treatment with HIV-1 and CXCL10,
indicating that it has an anti-inflammatory and neuro-
protective role. Hence, it is reasonable to expect that
treatment with bryostatin, which crosses the blood-brain
barrier, can decrease the migration of lymphocytes and
monocytes or macrophages into the brain by affecting
the expression of chemokines and cytokines in the
setting of HIV infection in the brain.
Overall, we conclude not only that CXCL10 is upregu-
lated in HIV-D patients, but that, in combination with
HIV-1, can have a profound impact on neuroglial health in
the neuro-HIV-1 infection setting (Figure 11). Bryostatin, a
PKC activator, conferred neuroprotection against HIV-1
and CXCL10. Thus, we report for the first time that bryos-
tatin can prevent neuronal damage and PBMC chemotaxis
induced by HIV-1 and CXCL10 (Figures 9, 11). Although
therapeutic targeting of chemokines in the brain may
have adverse consequences, current findings and earlier
published evidence suggest that CXCL10 could be a
strong candidate in impeding neuroinflammation.
Further understanding of the detailed molecular pathways
induced by HIV-1 and CXCL10 in neurons and astrocytes
will have great value in the design of novel neuroprotective
therapies.
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